CA-HOTWIRE
30.9.2021 15:02:25 CEST | Business Wire | Press release
Hotwire, the global tech communications consultancy, is welcoming new leaders as the company continues further expansion of its capabilities and adds new, innovative brands to the client roster.
Hotwire is building on its strategic acquisition of McDonald Butler Associates to unlock new possibilities of growth and present clients with a more robust communications offering and access to new skills and services. This new level of communication has been designed to build brand reputation, strengthen stakeholder relationships and deliver revenue growth, igniting the entire marketing ecosystem and supporting CMOs in growing their businesses.
“Technology and innovation leaders are continuing to manage complexity and are seeking out solutions to support,” said Heather Kernahan, global CEO of Hotwire. “This year we took steps to narrow the gaps that exist between marketing and sales with new integrated offerings and strengthened our relationships with clients as they navigated major shifts in their business. We’re also working with some amazing new brands and deepening our expertise and leadership across key areas of the business.”
New Leaders Support Rapid Growth
Hotwire continues to add senior leaders in strategy, planning, digital and client consulting to its teams across the world. This past quarter key hires have been made in Germany, the U.K., and the U.S.
In Germany, Martin Opercan joined Hotwire as a Senior Director, Strategic Growth and will be responsible for client strategy and planning. Martin brings over 20 years of experience in marketing, communications and business development and most recently oversaw the Munich office for diffferent.
Rebecca Rhodes and Anastasia Pavolva recently joined the Hotwire U.K. team. Rebecca is Head of Planning and before joining Hotwire, ran her own consultancy, SuperHuman and also previously was Global Chief Creative Officer at Golin. Anastasia is a Strategy Director with experience working in global agencies such as Ogilvy and in brand management at Procter & Gamble.
In the U.S., two new Senior Vice Presidents will join the leadership and client services team. Andrea Holland has worked in tech comms across large global brands including Intuit, PayPal and LegalZoom as well as early stage B2C tech startups. Andrea is a PR instructor and author for LinkedIn Learning and most recently ran her own consultancy, DialedPR. She also founded the nation's #1 jobs site for PR professionals looking for remote work, RemotePRJobs . Jessica Heagerty comes to Hotwire from Dell Technologies where she held roles in Analyst Relations and Field Marketing. Jessica started her career working for global brands in leading communications agencies.
Tech Innovators Choose Hotwire to Ignite New Opportunities
As Hotwire continues to provide a new level of communication expertise helping companies build brand reputation, strengthen stakeholder relationships and deliver revenue growth, it’s igniting the entire marketing ecosystem and supporting ambitious companies in growing their businesses.
New clients include fast growing and global innovators who selected Hotwire for its technology and innovation expertise and consultancy approach. Most recently, Hotwire signed on Aircall, BAM Karaoke, Bright Machines, Cobrainer, QA, Rocket App and Splashtop.
Award Winning Client Work and Global Recognition
Hotwire and individuals across the agency continue to gain recognition for leadership and impactful client work. Ludi Garcia, Managing Director of Hotwire Spain, was recently recognized as the #1 most admired communications professional in Spain by SCOPEN and Hotwire was named Best Comms PR consultancy, as voted for by PR professionals working in agencies.
Hotwire’s work on Zoomtopia, Zoom’s annual conference, received Honorable Mention for Ragan Comms' Media Relations Award for Virtual Event and is shortlisted in the PR report awards.
The company was also recently named in the Propel 100 list as one of the most influential PR agencies in the world in 2021.
Expanding Partnerships in The Tech Ecosystem
Hotwire is partnering with organizations across the world who are working to advance technology innovation and the leaders pushing the industry forward. The company is now a member of Tech UK , which brings together people, companies and organizations to realize the positive outcomes of what digital technology can achieve.
Hotwire is also a sponsor for Get On Board , which is a week of education and training to prepare women leaders for Board positions. The company is also a sponsor of Alley to the Valley , a community of accomplished women who fast-track business opportunities for each other. Hotwire supports board readiness and women in leadership with Executive Thought Leadership and Media Training and Speaker Readiness services.
To learn more about Hotwire, visit https://www.hotwireglobal.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005562/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
